Department of Neurology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Dermatopathologie Duisburg, Germany.
Mult Scler. 2018 Nov;24(13):1776-1778. doi: 10.1177/1352458518771276. Epub 2018 Oct 11.
Understanding the long-term effect of alemtuzumab on the immune system of multiple sclerosis (MS) patients is crucial.
To report a case of acute sarcoidosis (Löfgren's syndrome) in a relapsing-remitting MS patient, 1.5 years after the second course of alemtuzumab treatment.
Sarcoidosis was confirmed dermatohistologically, radiologically, and serologically. Analysis of the lymphocyte subpopulations showed a persistent effect of alemtuzumab treatment (CD4/CD8 ratio increased, absolute lymphocyte count of CD19-positive cells increased while CD3/4/8-positive cells were decreased).
Our case highlights the profound effect of alemtuzumab on the immune system and its possible risk for autoimmune complications.
了解阿仑单抗对多发性硬化症（MS）患者免疫系统的长期影响至关重要。
报告 1 例复发性 MS 患者在第 2 次阿仑单抗治疗后 1.5 年发生急性结节病（Löfgren 综合征）的病例。
结节病经皮肤组织病理学、影像学和血清学证实。淋巴细胞亚群分析显示阿仑单抗治疗具有持续效应（CD4/CD8 比值升高，CD19 阳性细胞绝对计数增加，而 CD3/4/8 阳性细胞减少）。
本病例强调了阿仑单抗对免疫系统的深远影响及其可能引发自身免疫并发症的风险。
